The immune response against platelets is a complex process involving many aspects of the innate and adaptive immune system. Immune destruction of platelets and megakaryocytes and the thrombocytopenia that ensues can cause different clinically significant haematological disorders such as foetal and neonatal alloimmune thrombocytopenia (FNAIT), transfusion-induced platelet refractoriness or immune thrombocytopenia (ITP). These conditions are frequently difficult to manage so an understanding of the biological nature of these adverse conditions is critical for an understanding of how to potentially reduce them. Superimposed on these immune platelet attack mechanisms are the immune characteristics of the platelets themselves. This paper will give an overview of how the immune system recognizes platelet antigens and mounts efficient effector mechanism to mediate thrombocytopenia. It will also present evidence to suggest that platelets also play a role in stimulating these responses and suppressing them: a scenario where the 'prey' can become the 'predator'.
Introduction

Innate and adaptive immunity and platelets
Innate immunity occurs naturally and is the result of the inherent genetic composition of the host. The innate immune system is comprised of non-specific defence mechanisms and is activated by danger signals derived from a wide variety of insults from tissue damage to infectious assaults. These signals affect many different aspects of host physiology such as anatomical barriers, for example the skin, secretions like stomach acid or lysozyme and cellular players such as neutrophils, macrophages and Natural Killer cells [1] [2] [3] [4] [5] . These different aspects work closely in unison to defend the host against infections in a relatively non-specific but direct manner within minutes to hours upon antigen appearance. One of the major functions of innate immunity is to recruit leucocytes to sites of inflammation caused by, for example, infections. This recruitment is mediated via the initial generation of potent molecules including lipid moieties, for example prostaglandins, chemokines and cytokines. Once recruited, leucocytes then initiate several host mechanisms of defence such as targeting infectious agents for destruction, enhancing the clearance of dangerous cells and, if necessary, recruitment and activation of the adaptive immune system through, for example, antigen presentation [1] [2] [3] [4] [5] .
On the other hand, adaptive immunity refers to the antigen-specific immune response comprised exclusively of B and T lymphocytes and, in contrast to innate immunity, this system is slow to react to infectious agents as its activation is dependent on whether the innate immune system calls it into play. Once recruited and activated, however, T and B lymphocytes are exquisitely specific for antigens via the expression of genetically rearranged receptors and are able to uniquely generate memory pools to mount a quick anamnestic response to a reoccurrence of the offending infection [1, 4] . It is now clear that adaptive and innate immunity are inextricably linked where the innate immune system appears to be the ultimate controller of both.
Platelets are the smallest circulating cells in the blood and are generated in the bone marrow from large parental cells called megakaryocyte in a process termed proplatelet-formation. Their primary physiological role is to maintain vascular integrity by responding to endothelial injury which leads to the eventual formation of a clot to arrest bleeding and initiate wound repair [6] [7] [8] . Platelets can also be targeted by the innate and adaptive immune system through for example, transfusion of allogeneic platelets, foetal/maternal incompatibility and autoimmune processes that attack the host's own platelets. What is fascinating though is that although platelets can be targeted by immunity and prematurely destroyed there are multiple lines of evidence to suggest that the platelets themselves have a critical role in the modulation of inflammatory and immune processes. In this scenario, the platelet 'prey' can, in some circumstances, become the 'predator' and significantly modulate host immunity and potentially dictate their own immunological fate. This paper will discuss how platelets are targeted by innate and adaptive immune processes and, perhaps more interestingly, how the platelets themselves may modulate host immunity.
Platelets as both prey and predator
Allo-and autoimmune destruction of platelets
Platelets express a cluster of human platelet antigens (HPAs) and their diversity has evolved due to singlenucleotide polymorphisms resulting in amino acid substitutions localized on the main platelet receptors: GPIIb/IIIa (integrin aIIbb3 or CD41/CD61: the fibrinogen receptor), the GPIb-V-IX (von Willebrand factor receptor) and the GPIa/IIa complex (a2b1, CD29, a collagen receptor) [9, 10] . HPA-15 is localized on the platelet membrane protein CD109 [a glycosylphosphatidylinositol (GPI)-linked glycoprotein located on the plasma membrane and belonging to the transforming growth factor-b receptor system] [11] . GPIIb-IIIa integrin also harbours the HPA1a/b antigens, the most clinically relevant platelet antigens in foetal or neonatal alloimmune thrombocytopenia (FNAIT) which is a potentially devastating bleeding disorder resulting in destruction of foetal platelets and which occurs when an HPA-negative mother is pregnant with a HPA-positive foetus and becomes alloimmunized against the foetal HPA antigens, upon mixing of foetal blood with the mother's blood [12, 13] . This results in the formation of anti-HPA-specific IgG-alloantibodies, which cross the placenta and destroy the foetal or neonatal platelets. This destruction occurs by phagocytes via their FcgRs which recognize and subsequently internalize the antibody-opsonized platelets via the Fc-tail of the anti-HPA alloantibody resulting in antibody-mediated platelet phagocytosis leading to foetal thrombocytopenia [12, 13] . Because antibody titre or isotype does not strictly correlate with FNAIT disease severity, other factors are likely to be involved. The strength of the interaction between IgG and FcgR indeed depends on several factors, such as the IgG subclass formed during the immune response, the relative affinity to FcgRs, the expression levels of FcgR allotypes, the FcgR copy number variation, various cytokines and importantly also the IgG-Fc glycosylation patterns [14] . IgG antibodies are glycoproteins which contain a branched sugar moiety attached to the Asn297 residue in their Fc region and this glycan is thus essential for the maintenance of a functional structure and for binding of IgG with FcgR [15] [16] [17] [18] . These glycans may contain variable amounts of galactose and sialic acid and may additionally carry a bisecting N-acetylglucosamine (GlcNAc) and core fucose. Variations in this carbohydrate composition can significantly affect antibody affinity to the FcgR and thereby antibody-mediated effector functions. It was found that anti-HPA-1a alloantibodies display lowered Fc-fucosylation [15] , which was shown to increase binding to FcgRIIIa/b, which enhanced antibody-mediated platelet phagocytosis [15] . Moreover, these fucosylation patterns correlated with increased clinical disease severity [15] . A follow-up study investigating 166 FNAIT cases confirmed these results and found using multiple logistic regression analysis that anti-HPA-1a-fucosylation combined with galactosylation and antibody levels correlated with bleeding severity [19] . Another factor which was found to influence anti-HPA-1a-mediated platelet phagocytosis in vitro, as well as antibody-mediated thrombocytopenia in vivo, was the acute phase protein C-reactive protein (CRP) [20] . CRP is a well-established biomarker for acute infections and inflammation. As CRP levels rapidly increase during acute infections and inflammation, they also seem to be functionally active in promoting antibody-mediated platelet destruction. Elevated CRP levels may therefore at least provide one explanation of why acute infections may trigger thrombocytopenia.
Allogeneic platelet transfusions also frequently trigger the formation of anti-human leucocyte antigen (HLA)-specific alloantibodies, which destroy the platelets in subsequent transfusions inducing a state of platelet refractoriness and depriving the transfused recipient from an effective transfusion [21] . Interestingly, anti-HLA antibodies from refractory thrombocytopenia patients do not display a decrease in Fc-fucosylation [15] , indicating a difference with anti-HPA-1a-mediated platelet destruction in FNAIT.
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts (<100*10 9 /l) [22] . In ITP, platelets are opsonized by platelet-specific IgG-autoantibodies, leading to FcgR-mediated platelet phagocytosis by splenic macrophages [23, 24] . However, the pathogenesis of ITP is highly complex [25, 26] , and two other forms of platelet destruction are also described in ITP, which are due to CD8+ cytotoxic T lymphocytes [27] or due to antiplatelet GPIIIa49-66 IgG antibodies which enabled platelet fragmentation independent of complement and through induction of reactive oxygen species (ROS) [28] . Initial management of ITP may include treatment with intravenous immunoglobulin (IVIg) [29] . The working mechanism of IVIg is actively under investigation and still a matter of debate. In the disease setting of ITP, IVIg may be effective therapeutically by activating FccRs on DCs [30] while other studies have suggested that IVIg is effective via sialic acid and SIGN-R1 (murine ortolog of human DC-SIGN on DCs) [31] . In addition, it has been described that IVIg may raise platelet counts in ITP by increasing peripheral numbers of tolerizing DCs [32] and CD4+CD25+FoxP3+ T regulatory cells [33] . Interestingly, CRP levels were also found to be increased in paediatric ITP patients and treatment with IVIg correlated with increased platelet counts, decreased levels of CRP and with reduced clinical bleeding severity [20] . Moreover, an increased CRP value at diagnosis appeared to be predictive for slower platelet count recovery after 3 months [20] . This was recently validated in a cohort of newly diagnosed adult ITP patients, in which increased CRP levels at diagnosis were shown to negatively predict platelet count recovery after treatment with steroids [34] .
Platelets as immune cells: the 'prey' becomes the 'predator'
Despite the fact that platelets are targeted for destruction in an allo-or autoimmune setting, it has now increasingly become clear that platelets are also capable of conveying non-haemostatic immune functions [35] [36] [37] . Platelets are able to battle invading pathogens and communicate with a variety of effector cells via sophisticated channels, thereby controlling immune responses. Platelets can sense the threat of invading pathogens or damage during inflammation, via their immune receptors called pattern recognition receptors. These include immunoglobulin or complement receptors as well as Toll like receptors (TLR, TLR1-9 are expressed on human and murine platelets) [23] . These receptors directly bind invading pathogens and microbes, including their derived products. Platelets can not only sense external danger signals, but also internal danger signals via TLR9, which was shown to be active during oxidative stress, through stimulation of platelet activation and granule secretion, aggregation in vitro and thrombosis in vivo [38] . Besides recognizing pathogens, platelets can also harbour pathogens on their plasma membrane as well as internally [39, 40] , including viruses [40, 41] , bacteria [42] [43] [44] and parasites [45] . Platelets can also surround or encapsulate the bacterium Staphylococcus aureus, driving the pathogen into clusters, thereby restricting the bacterial growth [46] . This was shown to occur via secretion of the antimicrobial peptide b-defensin and signalling through neutrophil extracellular traps (NETs) [46] . Bacteria (methicillin-resistant S. aureus and Bacillus cereus) were also trapped on hepatic Kupffer cells, dependent upon platelet-adhesion receptor GP1b [47] . Additionally, during sepsis neutrophils were also shown to be activated by platelet TLR4, which triggered the release of NETs in blood vessels, trapping bacteria in liver and lungs [48] . Platelets also appear to be involved in the clearance of bacterial infections, such as in infective endocarditis, where thrombin-stimulated platelets facilitated the clearance of streptococci [49] . Platelets could also redirect the course of the bacteria Listeria monocytogenes from less immunogenic phagocytes towards the more immunologically active splenic CD8a + dendritic cells, via GP1b and complement component C3 [50] . Furthermore, platelets can communicate with target cells via release of CD40L upon platelet activation, secretion of varies cytokines and chemokines, shedding of platelet microparticles and through their MHC class I [35] [36] [37] . Platelet-derived CD40L has been shown to enhance CD8+ T cell responses during infection with Listeria monocytogenes [51, 52] , bind to dendritic cells impairing differentiation, suppressing pro-inflammatory dendritic cell cytokines and increasing the anti-inflammatory dendritic cell cytokine IL-10 [53] . Platelets can also stimulate B cell differentiation and antibody-class switching through CD40L [54, 55] . Regarding the various cytokines and chemokines secreted by platelets, TGF-b levels for instance, seem regulated by platelets during ITP, as low levels of TGF-b were observed during active disease, while the levels normalized again upon effective treatment of ITP which increased the platelet counts [56, 57] . Platelets also facilitate communication via shedding of their platelet microparticles. Platelets can equip their microparticles with a hetergenous cargo, which can consist of various cytokines and chemokines, potent lipid mediators, enzymes, surface receptors (e.g., CD40L), autoantigens, nucleic acids (e.g., micro RNA), transcription factors or respiratory competent mitochondria [58] [59] [60] [61] [62] [63] [64] . So through their microparticles, platelets can efficiently regulate various immune functions, dependent on their specific cargo. Platelets carry two different MHC class I molecules: plasma membrane bound and intracellularly [65] . The MHC class I molecules on the platelet plasma membrane are mainly adsorbed from plasma and consist predominantly of denatured heavy chains. The membrane-bound MHC appears to be unstable because the molecules can passively dissociate from the platelet surface upon blood bank storage or upon elution with chloroquine diphosphate or acid washing without influencing the integrity of the platelet membrane [66] [67] [68] [69] [70] [71] [72] . Interestingly, these denatured MHC class I molecules are incapable of stimulating CD8+ T cell-mediated cytotoxicity [72] but can mediate an immunosuppressive-like reaction to transfused blood cells. In syngeneic settings, platelet activation can lead to expression of nascent MHC class I molecules, which are capable of presenting antigens to CD8+ T cells. Activated platelets were shown to present malarial peptides to malaria-specific T cells, resulting in enhanced immunity against the parasite [73] . Therefore, the response towards T cells (suppression or activation) seems to be dependent upon the type of MHC class I, plasma membrane-bound or intracellularly.
Conclusion
Platelets can be targeted and destroyed by the immune system in a variety of ways; however, evidence is accumulating that platelets themselves can critically modulate and regulate inflammatory immune responses as well. The platelet 'prey' has thus the ability to transform into the 'predator' and potentially dictate a plethora of biological immune responses.
